Publications

5808 Results

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective Phase 2 trials

Authors
G Sonpavde;G Pond;R Fougeray;TK Choueiri;A Qu;DJ Vaughn;G Niegisch;P Albers;ND James;YN Wong;YJ Ko;SS Sridhar;MD Galsky;DP Petrylak;U Vaishampayan;A Khan;N Vogelzang;T Beer;WM Stadler;PH O'Donnell;CN Sternberg;JE Rosenberg
Journal / Conference
European Urology, 63(4):717-723
Year
2013
Research Committee(s)
Genitourinary
PMID
PMID23206856
PMC
PMC4127896
Study Number(s)
S0031, S0306

Cooperative group clinical trials in general thoracic surgery: report from the 2012 Robert Ginsberg Clinical Trials Meeting of the General Thoracic Surgical Club

Authors
M Allen;D Wigle;K Kernstine
Journal / Conference
Annals of Thoracic Surgery 95(2):750-756
Year
2013
Research Committee(s)
Lung
PMID
PMID23336898
PMC
Reviews not within the scope of the Public Access Policy

Factors associated with retention of African-American and white participants in a prostate cancer prevention trial

Authors
JA Hermos;K Arnold;E Cook;K Anderson;J Probstfield
Journal / Conference
Society for Clinical Trials Annual Meeting (May 19-22, 2013, Boston, MA), poster presentation
Year
2013
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Clinical, genomic, and imaging predictors of malignancy: analysis ofthe first U.S. cooperative group prospective clinical trial in symptomatic monoclonal gammopathies (SWOG S0120)

Authors
MV Dhodapkar;R Sexton;S Waheed;SZ Usmani;XD Papanikolaou;BP Nair;NM Petty;JD Shaughnessy;A Hoering;J Crowley;RZ Orlowski;B Barlogie
Journal / Conference
Journal of Clinical Oncology 31(suppl; abstr 8515); ASCO annual meeting 2013, oral presentation
Year
2013
Research Committee(s)
Myeloma
Study Number(s)
S0120

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

Authors
S Nand;M Othus;JE Godwin;CL Willman;TH Norwood;DS Howard;SE Coutre;HP Erba;FR Appelbaum
Journal / Conference
Blood 122(20):3432-3439;
Year
2013
Research Committee(s)
Leukemia
PMID
PMID24092933
PMC
PMC3829116
Study Number(s)
S0703

Should modest elevations in prostate specific antigen or international prostate symptom score, or their rates of increase over time, be used as surrogate measures of incident benign prostatic hyperplasia?

Authors
J Schenk;R Hunter-Merrill;Y Zheng;R Etzioni;R Gulati;C Tangen;IM Thompson;A Kristal
Journal / Conference
American Journal of Epidemiology 178(5):741-751;
Year
2013
Research Committee(s)
Cancer Control
PMID
PMID23813705
PMC
PMC3755644
Study Number(s)
SWOG-9217

Phase IIB randomized double-blind placebo-controlled biomarker modulation study of high dose vitamin D in premenopausal women at high-risk for breast cancer: SWOG S0812

Authors
K Crew;D Lew;D Hershman;S Refice;G Anderson;G Hortobagyi;G Goodman;P Brown
Journal / Conference
San Antonio Breast Cancer Symposium, abstr. OT3-3-02; poster presentation;
Year
2013
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0812

SWOG S0500 - a randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

Authors
J Smerage;W Barlow;D Hayes;E Winer;B Leyland-Jones;G Srkalovic;S Tejwani;A Schott;MA O'Rourke;D Lew;J Gralow;RB Livingston;GN Hortobagyi
Journal / Conference
San Antonio Breast Cancer Symposium, abst. S5-07; oral presentation;
Year
2013
Research Committee(s)
Breast
Study Number(s)
S0500

Prognostic value of tumor-infiltrating lympocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Authors
S Adams;R Gray;S Demaria;LJ Goldstein;EA Perez;LN Shulman;S Martino;NE Davidson;G Sledge;J Sparano;S Bavde
Journal / Conference
San Antonio Breast Cancer Symposium, abst S1-07; oral presentation;
Year
2013
Research Committee(s)
Breast
Study Number(s)
E1199, E2197

Prospective evaluation of the utility of the international prognostic score (IPS) for patients with advanced hodgkin lymphoma (HL) treated with contemporary therapy: results from US intergroup trial E2496

Authors
CS Diefenbach;L Hong;LI Gordon;RI Fisher;NL Bartlett;JM Connors;RD Gascoyne;H Wagner;P Stiff;B Cheson;M Gospodarowicz;BS Kahl;JW Friedberg;KH Blum;TM Habermann;JM Tuscano;RT Hoppe;SJ Horning;R Advani
Journal / Conference
Haematologica 98(supplement 2):P010;CS, p.4; International Symposium on Hodgkin Lymphoma (Oct.12-15, 2013, Cologne, Germany), poster presenttion;
Year
2013
Research Committee(s)
Lymphoma
Study Number(s)
E2496